Figures & data
Figure 1. Humanizing mice for identification of novel drugs targeting human iNKT cells for anticancer therapies. α-galactosylceramide (α-GalCer) can potently stimulate the antitumor activity of invariant natural killer T (iNKT) cells in wild-type mice (left). Due to the high affinity of human CD1d to murine iNKT T-cell receptors (TCRs), α-GalCer exhibits robust antitumor functions also in hCD1d-KI mice (central left). Novel α-GalCer analogs that will demonstrate potent antitumor activity in vivo in models incorporating both human CD1d and human iNKT TCRs (central right) will be most promising candidates for iNKT cell-based anticancer immunotherapy (right).
